



ASX & MEDIA RELEASE

2 MARCH 2018

PROGRESS TO DATE ON MEDLAB'S UNIQUE NANO-PARTICLE THC/CBD BUCCAL CANNABIS SPRAY FOR PAIN MANAGEMENT (NANABIS™)

Medlab (ASX: MDC) is pleased to advise that progress to date on our pain management product, Nanabis™ is in line with plan as follows:

- Medlab commenced medical Education Seminars in Sydney last week. Similar seminars will take place in Melbourne and Brisbane in the following weeks with approximately 500 total attendees expected.
- The first batch of Nanabis™ product has been manufactured by PPP in Melbourne and validated analytical release for supply is expected by 8th March 2018.
- The Australian Government via the "Office of Drug Control (ODC)" has formally licenced Medlab as a supplier of Nanabis™.

In keeping with the TGA's Special Access Scheme (SAS) Medlab has instituted the foregoing Medical Education Seminars. These seminars are designed for appropriate Health Professionals and will assist them in understanding:

- The Royal North Shore Hospital human trial aims with Nanabis™;
- Nanabis™ use for Pain Management; and
- Special Access Scheme as it relates to the appropriate supply of Cannabis

Once the "validated release" of the manufactured Nanabis™ product is achieved Medlab will be in a position to supply a drug that conforms to Australian standards for a Schedule 8 medicine.

Medlab's Managing Director, Dr Sean Hall commented, "that Nanabis™ is an Australian produced medicine made to Australian standards in an Australian approved facility with a unique delivery system (Nanocelle™) and will be supported by trial data thus giving prescribers confidence in quality and efficacy."

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.